Ignite Creation Date:
2024-05-06 @ 8:28 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06393374
Status:
RECRUITING
Last Update Posted:
2024-07-11
First Post:
2024-04-26
Brief Title:
Sacituzumab Tirumotecan MK-2870 Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR MK-2870-012
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-06-24
Start Date Type:
ACTUAL
Primary Completion Date:
2030-12-16
Primary Completion Date Type:
ESTIMATED
Completion Date:
2037-12-14
Completion Date Type:
ESTIMATED
First Submit Date:
2024-04-26
First Submit QC Date:
April 26 2024
Study First Post Date:
2024-05-01
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-17
Last Update Post Date:
2024-07-11
Last Update Post Date Type:
ACTUAL